Male Reproductive and Urinary Health: Anatomy, Hormones, and Conditions

When testosterone production is insufficient, the condition is known as hypogonadism. This is categorized into two types:

• Primary Hypogonadism: A direct defect in the testes (e.g., Klinefelter syndrome, trauma, or infections like mumps).
• Secondary Hypogonadism: A failure of the regulatory signals from the hypothalamus or pituitary gland (e.g., due to tumors).

Common symptoms include decreased libido, erectile dysfunction, loss of muscle mass, and psychological shifts like depression. To manage these symptoms, clinicians may prescribe Testosterone Replacement Therapy (TRT) via injections, gels, or patches, though patients must be monitored for risks such as cardiovascular issues or prostate health concerns.

Prostate Health and Benign Prostatic Hyperplasia (BPH)

The prostate is a walnut-sized gland that surrounds the prostatic urethra. While androgens are necessary for its function, age-related hormonal shifts can lead to pathology. Specifically, testosterone is metabolized into dihydrotestosterone (DHT) by the enzyme 5-alpha-reductase. Increased levels of DHT, combined with increased prostate cell sensitivity to the hormone, can lead to Benign Prostatic Hyperplasia (BPH).

BPH is a non-cancerous enlargement of the prostate caused by the hyperplasia (increased number) of stromal and epithelial cells. As the prostate grows, it compresses the urethra, leading to Lower Urinary Tract Symptoms (LUTS), such as:

• Urinary frequency and urgency.
• Difficulty initiating urination or weak stream.

Clinical Note: Diagnostic Approach to BPH To differentiate BPH from more serious conditions like prostate cancer, clinicians typically use a combination of:

1. Digital Rectal Exam (DRE): To palpate the size, shape, and texture of the prostate.
2. Serum PSA (Prostate-Specific Antigen): A protein produced by the prostate. Levels $>4.0 \text{ ng/mL}$ may indicate BPH, prostatitis, or cancer.
3. Urinalysis: To check for blood or infection.

If BPH becomes severe and pharmacological treatments fail, a surgical intervention called Transurethral Resection of the Prostate (TURP) may be required. In this minimally invasive procedure, a resectoscope is used to remove the excess prostate tissue obstructing the urethra.

The Urinary System and the Micturition Process

The urinary system relies on the coordinated effort of the bladder and the urethral sphincters to manage waste. The bladder is a muscular sac characterized by an outer layer called the detrusor muscle.

Micturition (the act of urination) follows a specific physiological sequence:

1. Filling: As the bladder fills, stretch receptors in the bladder wall send signals to the brain.
2. Contraction: The detrusor muscle contracts, increasing internal pressure.
3. Involuntary Relaxation: The internal urethral sphincter (involuntary) relaxes.
4. Voluntary Relaxation: The external urethral sphincter (voluntary) relaxes, allowing urine to exit the body.

Disruptions in Bladder Control: UI and OAB

When the micturition process is disrupted, patients may experience Urinary Incontinence (UI) or Overactive Bladder (OAB).

• Urinary Incontinence (UI): This is the general loss of bladder control. It can manifest as stress incontinence (leakage during physical activity) or urge incontinence (leakage following a sudden urge).
• Overactive Bladder (OAB): This is a specific disorder characterized by an overwhelming, sudden urge to urinate. OAB is caused by the inappropriate stimulation of muscarinic receptors on the detrusor muscle. Specifically, the M3 receptor is the primary mediator of these involuntary contractions.

Clinical indicators of OAB include:

• Urinary frequency: Voiding $\ge 8$ times during waking hours.
• Nocturia: Waking up $\ge 2$ times during the night to urinate.

While OAB is common in older adults, it is important to note that it is a pathological condition and not a normal part of the aging process.